ASSERTIO HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8282 USD | +5.49% |
|
+7.14% | -22.60% |
| Sales 2024 * | 117M 9.37B | Sales 2025 * | 130M 10.39B | Capitalization | 78.78M 6.29B |
|---|---|---|---|---|---|
| Net income 2024 * | -11M -878M | Net income 2025 * | 1M 79.85M | EV / Sales 2024 * | 0.67 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.61 x |
| P/E ratio 2024 * |
-6.9
x | P/E ratio 2025 * |
166
x | Employees | 53 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Assertio Holdings, Inc.
More recommendations
More press releases
| 1 day | +5.49% | ||
| 1 week | +7.14% | ||
| Current month | -13.67% | ||
| 1 month | -13.67% | ||
| 3 months | -5.64% | ||
| 6 months | -61.12% | ||
| Current year | -22.60% |
1 week
0.73
0.94
1 month
0.730.97
Current year
0.731.21
1 year
0.738.01
3 years
0.738.01
5 years
0.7319.68
10 years
0.73134.96
| Managers | Title | Age | Since |
|---|---|---|---|
Heather Mason
CEO | Chief Executive Officer | 63 | 31/01/19 |
Ajay Patel
DFI | Director of Finance/CFO | 40 | 30/06/19 |
Howard Franklin
CTO | Chief Tech/Sci/R&D Officer | - | 05/03/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Staple
CHM | Chairman | 72 | 31/10/03 |
James Tyree
BRD | Director/Board Member | 71 | 30/09/16 |
William McKee
BRD | Director/Board Member | 62 | 28/02/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.47% | 29 M€ | -4.33% | ||
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.8282 | +5.49% | 670,762 |
| 25/04/24 | 0.7851 | -9.30% | 2,915,874 |
| 24/04/24 | 0.8656 | -4.83% | 798,757 |
| 23/04/24 | 0.9095 | +5.11% | 1,100,564 |
| 22/04/24 | 0.8653 | +11.94% | 735,543 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâs primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Sector
Pharmaceuticals
Calendar
05/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8282
USD
Average target price
3
USD
Spread / Average Target
+262.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.60% | 78.78M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ASRT Stock
